THE measurement of serum free thyroxine (FT4), which forms a small fraction (0.01-0.05 per cent) of the circulating total thyroxine (TT4), might be expected to provide the most accurate single biochemical index of thyroid status, on the basis that only free hormone is bioavailable. The conventional estimation of FT4 by equilibrium dialysis' is time consuming and the arrival of radioimmunoassay kits suitable for routine clinical use has been eagerly awaited. We have assessed one such kit (Amerlex free T4) incorporating an 1125 labelled thyroxine analogue and an antithyroxine antibody which binds both the analogue and free, but not protein bound, thyroxine. The competition for antibody binding sites between the known amount of analogue and the unknown amount of free thyroxine allows measurement of the free thyroxine. We have compared the clinical usefulness of FT4 measured by this technique with that of the more traditional thyroid function tests (TT4 and a derived free thyroxine index, FT4I).
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PATIENTS AND METHODS
One hundred and one consecutive patients attending the thyroid clinic at the Royal Victoria Hospital were studied. Ten were clinically hyperthyroid, six clinically hypothyroid and the remaining 85 were clinically euthyroid, comprising previously hypothyroid patients stabilized on thyroxine replacement, post-radioiodine follow A grant has been made from the Royal Victoria Hospital Metabolic Unit Research Fund for the cost of illustrations.
up patients, hyperthyroid patients during a course of antithyroid drug treatment and patients with simple goitre. Patients on thyroxine had been instructed to take their medication as a single dose in the morning. Fifty-two healthy euthyroid controls (hospital staff and medical students), 23 euthyroid pregnant females (second and third trimester) attending the Royal Maternity Hospital, and 10 hospital in-patients with severe non-thyroidal illness (upper abdominal neoplasia, 2; hepatic failure due to cirrhosis, 3; Crohn's disease, 1; renal failure, 1; chronic leukaemia, 1; cardiac failure, 1) were also studied.
FT4, TT4 and FT4I were measured on mid afternoon serum samples and previous treatment of thyroid disease and current therapy were noted. Clinical thyroid status at the time of the blood tests was assessed by one of the authors using standard clinical techniques. Clinical hypothyroidism was confirmed by an elevated TSH level, and all the patients with non-thyroidal illness had normal serum TSH.
Serum FT4 was measured using the Amerlex free T4 kit (Radiochemical Centre, Amersham, UK). Serum TT4 was measured by radioimmunoassay using solid phase thyroxine antiserum (Advanced Laboratory Techniques) and the free thyroxine index was calculated from the ratio of TT4 to available thyroid hormone binding sites measured by the uptake of 1 131 triiodothyronine (MAA kit, Amersham, UK).
The normal ranges (mean -i-2 SD) for FT4 (14.8 -26.4 pmol/l), TT4 (72-134 nmol/l), and FT4I (67-127), were derived from the control group in the present study. FT4 in 32 euthyroid patients on thyroxine therapy (mean daily dosage 0.13 mg) was significantly higher than in 53 euthyroid patients not on thyroxine, and also higher than in controls: 9 of these 32 patients had FT4 values in the hyperthyroid range (mean daily dosage 0.16 mg) and in five, FT4 was grossly elevated. In the 32 euthyroid patients on thyroxine, mean TT4 and FT4I were also higher than in the 53 patients not on thyroxine, but were not significantly different from the 52 controls. Only five patients on thyroxine had TT4 values in the hyperthyroid range, while six had FT4I values in the hyperthyroid range.
RESULTS
In euthyroid pregnancy FT4 was lower and TT4 was higher than in controls. FT4I values were similar in the pregnant and non-pregnant states.
In severe non-thyroidal illness mean values of all tests (FT4, TT4, and FT4J) were lower than in the healthy controls.
To study the response of each assay to a dose of oral thyroxine, blood samples were taken from two of the controls at frequent intervals over a 48 hour period, a single dose of oral thyroxine (0.3 mg) being taken after 24 hours (Figure 4 ). In this preliminary study there was a stable baseline without evidence of circadian variation for each of the three assays. Also there was no evidence that following oral thyroxine, the free hormone rose out of proportion to the bound fraction, nor that it fell away more rapidly. hypothyroid patients given enough thyroxine to normalise both baseline TSH2 and the TSH response to thyrotropin releasing hormone.3 This may reflect a need for relatively higher concentrations of exogenous thyroxine to compensate for the failure of direct triiodothyronine production by the thyroid gland. Though in our study, TT4 and FT4I were also elevated in euthyroid patients on thyroxine, the distribution of these values above the upper limit of normal was less markedly skewed than that of the FT4 values. In some patients on thyroxine ( In non-thyroidal illness both thyroxine clearance and FT4 are generally considered to be normal,8 though low TT4 is well recognised.9 We found low FT4 concentrations perhaps because of unforeseen binding of the analogue to low affinity serum proteins, which may be reduced in non-thyroidal illness. Normal values of FT4 have been reported with a number of other FT4 radioimmunoassay kits in this situation. '°0"
Falsely high readings with this assay have been obtained in the rare condition of familial euthyroid thyroxine excess'2 and also in the presence of antithyroxine antibodies;'3 this is due to analogue binding to albumin and antibody respectively.
The concept that in euthyroid states FT4 levels lie within the normal range irrespective of alterations in thyroid binding proteins is perhaps an oversimplification. Circulating protein bound hormone does not just represent an inert store, but is involved in the dynamics of tissue hormone supply. Thus the goal of a single thyroid hormone test which reads within the same normal range in all euthyroid states may be unattainable. Nevertheless tests which most nearly do this will be easiest to interpret in clinical practice. In our study this appeared to be FT4I. While results from the Amerlex free T4 assay may be of considerable value, those using it as a screening test should be aware of the altered normal range in pregnancy and non-thyroidal illness, and of the difficulties of interpreting results in patients on thyroxine therapy.
SUMMARY
The clinical usefulness of a free thyroxine (FT4) radioimmunoassay (Amerlex) was compared with a total thyroxine (TT4) radioimmunoassay and with a derived free thyroxine index (FT4I). In hyperthyroid patients FT4 gave a clearer separation from normal than TT4 or FT4I. In 32 clinically euthyroid patients taking thyroxine, mean values of all three tests were greater (p < 0.001) than in 53 clinically euthyroid patients not taking thyroxine, although in five of the 32 on thyroxine, FT4 (but not TT4 or FT4I) was grossly elevated. FT4 may detect overtreatment in apparently euthyroid patients. In severely ill patients all three tests gave lower values (p < 0.001) than in controls. In euthyroid pregnancy FT4 was lower (p < 0.001) and TT4 higher (p < 0.001) than in controls; FT4I in pregnancy was similar to controls. Clinicians using the Amerlex free thyroxine assay should be aware of the altered range of normality in pregnancy, non-thyroidal illness and in thyroxine treated patients. 
